Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay

Journal of Virological Methods

Volumn 171, Issue 1, 2011, Pages 67-73

  Tadokoro, Kenichi ^a   Suzuki, Fumitaka ^b   Kobayashi, Mariko ^c   Yamaguchi, Toshikazu ^a   Nagano, Makoto ^a   Egashira, Toru ^a   Kumada, Hiromitsu ^b  

^a Kawagoe shi   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Toranomon Branch Hospital   (Japan)

Author keywords

Drug resistant mutation; Entecavir; Hepatitis B virus; Lamivudine; PCR Invader

Indexed keywords

ENTECAVIR; LAMIVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VIRUS MUTANT; VIRUS MUTATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 78650559440     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.10.001     Document Type: Article

References (18)

1. Degertekin B., Hussain M., Tan J., Oberhelman K., Lok A.S. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 2008, 50:42-48.
2. Germer J.J., Majewski D.W., Yung B., Mitchell P.S., Yao J.D. Evaluation of the invader assay for genotyping hepatitis C virus. J. Clin. Microbiol. 2006, 44:318-323.
3. Hashimoto Y., Suzuki F., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H., Hosaka T., Akuta N., Kobayashi M., Saito S., Suzuki Y., Kobayashi M., Arase Y., Ikeda K., Kumada H. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J. Med. Virol. 2010, 82:684-691.
4. Ke S.H., Madison E.L. Rapid and efficient site-directed mutagenesis by single-tube megaprimer PCR method. Nucleic Acids Res. 1997, 25:3371-3372.
5. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., Chung Y.H., Lee Y.S., Yoo W., Kim S.O. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43:1385-1391.
6. Libbrecht E., Doutreloigne J., Van De Velde H., Yuen M.F., Lai C.L., Shapiro F., Sablon E. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment assessed by a line probe assay. J. Clin. Microbiol. 2007, 45:3935-3941.
7. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol. Int. 2008, 2:147-151.
8. Lyamichev V.I., Kaiser M.W., Lyamicheva N.E., Vologodskii A.V., Hall J.G., Ma W.P., Allawi H.T., Neri B.P. Experimental and theoretical analysis of the invasive signal amplification reaction. Biochemistry 2000, 39:9523-9532.
9. Manigold T., Rehermann B. Chronic hepatitis B and hepatocarcinogenesis: does prevention of "collateral damage" bring the cure?. Hepatology 2003, 37:707-710.
10. Mashima Y., Nagano M., Funayama T., Zhang Q., Egashira T., Kudho J., Shimizu N., Oguchi Y. Rapid quantification of the heteroplasmy of mutant mitochondrial DNAs in Leber's hereditary optic neuropathy using the Invader technology. Clin. Biochem. 2004, 37:268-276.
11. Suzuki F., Tsubota A., Arase Y., Suzuki Y., Akuta N., Hosaka T., Someya T., Kobayashi M., Saitoh S., Ikeda K., Kobayashi M., Matsuda M., Satoh J., Takagi K., Kumada H. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003, 46:182-189.
12. Suzuki F., Akuta N., Suzuki Y., Yatsuji H., Sezaki H., Arase Y., Hirakawa M., Kawamura Y., Hosaka T., Kobayashi M., Saitoh S., Ikeda K., Kobayashi M., Watahiki S., Kumada H. Efficacy of switching to entecavir monotherapy in Japaneselamivudine-pretreated patients. J. Gastroenterol. Hepatol. 2010, 25(May (5)):892-898.
13. Tadokoro K., Kobayashi M., Yamaguchi T., Suzuki F., Miyauchi S., Egashira T., Kumada H. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J. Virol. Methods 2006, 138:30-39.
14. Tenney D.J., Rose R.E., Baldick C.J., Levine S.M., Pokornowski K.A., Walsh A.W., Fang J., Yu C.F., Zhang S., Mazzucco C.E., Eggers B., Hsu M., Plym M.J., Poundstone P., Yang J., Colonno R.J. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance mutations present. Antimicrob. Agents Chemother. 2007, 51:902-911.
15. Villet S., Ollivet A., Pichoud C., Barraud L., Villeneuve J.P., Trépo C., Zoulim F. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007, 46:531-538.
16. Yatsuji H., Suzuki F., Sezaki H., Akuta N., Suzuki Y., Kawamura Y., Hosaka T., Kobayashi M., Saitoh S., Arase Y., Ikeda K., Watahiki S., Iwasaki S., Kobayashi M., Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol. 2008, 48:923-931.
17. Zhang X., Liu C., Gong Q., Zhang S., Zhang D., Lu Z., Wang Y. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J. Gastroenterol. Hepatol. 2003, 18:1353-1357.
18. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.